Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review

  • ID: 4285212
  • SWOT Analysis
  • 47 pages
  • GlobalData
  • Aerie Pharmaceuticals
1 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Celldex Therapeutics Inc
  • MORE
Aerie Pharmaceuticals Inc (AERI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities - A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Aerie Pharmaceuticals Inc (Aerie) is a pharmaceutical company that discovers, develops and commercializes therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates comprise rhopressa, a once-daily eye drop which is used for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; and roclatan, a fixed-dose combination of rhopressa and latanoprost. Aerie works in partnership with other pharma companies and universities for drug discovery technologies. The company has presence in the US and Ireland. Aerie is headquartered in Irvine, California, the US.

Aerie Pharmaceuticals Inc Key Recent Developments

May 08, 2018 Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
May 01, 2018 Aerie Pharmaceuticals Names Concetta Perro As Commercial Counsel
Apr 12, 2018 Aerie Pharmaceuticals Announces Appointment Of Scott Laranjo As Director, Marketing, Roclatan
Feb 28, 2018 Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acucela Inc
  • Celldex Therapeutics Inc
  • MORE
Section 1 - About the Company
  • Aerie Pharmaceuticals Inc - Key Facts
  • Aerie Pharmaceuticals Inc - Key Employees
  • Aerie Pharmaceuticals Inc - Key Employee Biographies
  • Aerie Pharmaceuticals Inc - Major Products and Services
  • Aerie Pharmaceuticals Inc - History
  • Aerie Pharmaceuticals Inc - Company Statement
  • Aerie Pharmaceuticals Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Aerie Pharmaceuticals Inc - Business Description
  • R&D Overview
  • Aerie Pharmaceuticals Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Aerie Pharmaceuticals Inc - Strengths
  • Aerie Pharmaceuticals Inc - Weaknesses
  • Aerie Pharmaceuticals Inc - Opportunities
  • Aerie Pharmaceuticals Inc - Threats
  • Aerie Pharmaceuticals Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Aerie Pharmaceuticals Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 08, 2018: Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
  • Apr 12, 2018: Aerie Pharmaceuticals Announces Appointment Of Scott Laranjo As Director, Marketing, Roclatan
  • Feb 28, 2018: Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update and 2018 Guidance
  • Feb 21, 2018: New glaucoma drugs yield large, lasting reductions in intraocular pressure
  • Feb 12, 2018: Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region
  • Feb 08, 2018: Aerie Pharmaceuticals Announces Appointment of Brad Fuller as Director of National Accounts in its Market Access Department
  • Feb 01, 2018: Aerie Pharmaceuticals Announces Appointment of Tad Heitmann as Head of Communications
  • Jan 16, 2018: Aerie Pharmaceuticals Announces Appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance and Tim Swan as Director of Sales and Transparency Operations
  • Jan 02, 2018: Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs
  • Dec 04, 2017: Aerie Pharmaceuticals Announces Appointment of Heather Johnson as Regional Sales Director for the Northeast Region
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About
  • Contact
  • Disclaimer
List of Tables
  • Aerie Pharmaceuticals Inc, Key Facts
  • Aerie Pharmaceuticals Inc, Key Employees
  • Aerie Pharmaceuticals Inc, Key Employee Biographies
  • Aerie Pharmaceuticals Inc, Major Products and Services
  • Aerie Pharmaceuticals Inc, History
  • Aerie Pharmaceuticals Inc, Other Locations
  • Aerie Pharmaceuticals Inc, Subsidiaries
  • Aerie Pharmaceuticals Inc, Key Competitors
  • Aerie Pharmaceuticals Inc, Ratios based on current share price
  • Aerie Pharmaceuticals Inc, Annual Ratios
  • Aerie Pharmaceuticals Inc, Annual Ratios (Cont...1)
  • Aerie Pharmaceuticals Inc, Interim Ratios
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
  • Aerie Pharmaceuticals Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Aerie Pharmaceuticals Inc, Performance Chart (2013 - 2017)
  • Aerie Pharmaceuticals Inc, Ratio Charts
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
  • Aerie Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Acucela Inc
  • Celldex Therapeutics Inc
  • Inotek Pharmaceuticals Corp
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll